Clinical Trial

Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the objective response rate (ORR) to lorigerlimab in patients with refractory pancreatic ductal adenocarcinoma (PDAC) and pathogenic germline variants (PGVs) in breast cancer type 1 or 2 susceptibility protein (BRCA1/2), Partner and Localizer of BRCA2 (PALB2) and radiation sensitive protein 51 C or D (RAD51C/D).
Trial Details
NCT Number NCT07565155
Lead Sponsor Peter Hosein, MD
Collaborators: MacroGenics
Conditions Pancreatic Adenocarcinoma, Homologous Recombination Deficiency
Enrollment 40 participants
Start Date 2026-06-01
Primary Completion 2031-06-01 (estimated)
Study Completion 2031-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-04